^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
MPT-0118
i
Other names: MPT-0118
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Monopteros Therap
Drug class:
MALT1 protein inhibitor
Related drugs:
over1year
First-in-human study of MALT1 inhibitor MPT-0118: Results from monotherapy dose escalation in advanced or metastatic refractory solid tumors (ESMO 2023)
Clinical trial identification NCT04859777. The biomarker data are consistent with the purported mechanism. The results warrant advancing to study Part B in combination with pembrolizumab.
P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • MALT1 (MALT1 Paracaspase)
|
IFNG expression
|
Keytruda (pembrolizumab) • MPT-0118
over1year
Translational Studies Using the MALT1 Inhibitor (S)-Mepazine to Induce Treg Fragility and Potentiate Immune Checkpoint Therapy in Cancer. (PubMed, J Immunother Precis Oncol)
Activity in syngeneic tumor models and human PDOTS was likely mediated by induction of tumor-associated Treg fragility. This translational study supports ongoing clinical investigations (ClinicalTrials.gov Identifier: NCT04859777) of MPT-0118, (S)-mepazine succinate, in patients with advanced or metastatic treatment-refractory solid tumors.
Journal
|
MALT1 (MALT1 Paracaspase)
|
MPT-0118
2years
P1 data • Combination therapy
|
MALT1 (MALT1 Paracaspase)
|
Keytruda (pembrolizumab) • MPT-0118
over3years
[VIRTUAL] MPT-0118 a clinical drug candidate to assess Treg reprogramming via MALT1 blockade (ESMO 2021)
MPT-0118 Treg reprogramming represents a novel strategy with the potential to mitigate the critical problem of low ICT response rates in solid tumors. MPT-0118 recently started a phase 1/1b dose-escalation and cohort-expansion clinical trial.
Clinical
|
IFNG (Interferon, gamma) • MALT1 (MALT1 Paracaspase)
|
MPT-0118
Share via
